NRX Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1201 ORANGE STREET, WILMINGTON, DE, 19801
Mailing Address 1201 ORANGE STREET, WILMINGTON, DE, 19801
Phone 484-254-6134
Fiscal Year End 1231
EIN 822844431
Financial Overview
FY2024
-$25.13M
Net Income
$26.87M
Total Liabilities
$7.41M
Stockholders' Equity
$4.59M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
| 8-K Current report of material events | December 29, 2025 | View on SEC |
| S-3/A Shelf registration amendment | December 12, 2025 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 8-K/A Current report amendment | November 21, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 8-K Current report of material events | October 23, 2025 | View on SEC |
| 8-K Current report of material events | September 26, 2025 | View on SEC |
| 8-K Current report of material events | September 12, 2025 | View on SEC |
Material Events
8-K Legal Issue January 16, 2026
High Impact
- No immediate impact on the trading of NRX Pharmaceuticals' common stock (NRXP) or warrants (NRXPW).
- The company has proactively scheduled its 2025 Annual Meeting for March 23, 2026.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.